Danaher Raises Full-Year EPS Guidance Following Strong Q3 2026 Results
Danaher (DHR) reported strong third-quarter 2026 earnings, characterized by higher-than-expected revenue and earnings per share. The company raised its full-year EPS guidance, driven by accelerating demand in the bioprocessing and clinical diagnostics markets. Management noted that after years of portfolio restructuring, the strategic focus has shifted toward driving organic growth and increasing market share across existing operating units. Key drivers included mid-teens order growth in biotechnology segments, particularly within upstream consumables and reagents. As biopharma demand recovers, Danaher is leveraging its Danaher Business System (DBS) to improve commercial execution and integrate artificial intelligence into laboratory workflows. Looking toward 2027, the company expects core revenue growth (excluding respiratory products) to land between 4% and 5%.
Tickers: $DHR
Topics: bioprocessing clinical diagnostics earnings guidance M&A strategy revenue growth